Close Menu

NEW YORK (360Dx) – T2 Biosystems announced on Tuesday that it has begun a public offering of 5.657 million shares of its common stock.

T2 Bio has not yet priced its shares. It said that it will grant the underwriters a 30-day option to purchase up to an additional 847,500 shares of its common stock.

Leerink Partners will act as joint book-running manager for the offering, while Canaccord Genuity will act as passive book-running manager. In addition, Janney Montgomery Scott, JonesTrading Services, and WBB Securities will act as co-managers for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.